Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Clinical Characteristics and Treatment Allocations in Patients with Myelodysplastic Syndromes and Monosomy 7: Results from an International Multicenter Study Suggest That Hypomethylating Agents Significantly Improve Overall- and AML-Free Survival in Patients Classified As Very High Risk By IPSS-R

Julie Schanz, MD PhD, Friederike Braulke, MD, Ghulam J. Mufti, MD PhD, Elena Crisà, Austin Kulasekararaj, Kathrin Nachtkamp, MD, Ulrich Germing, Stefan Schmitz, MD PhD, Peter Haas, MD, Michael Lübbert, Catharina Müller-Thomas, MD, Katharina Götze, Uwe Platzbecker, MD, Florian Nolte, Wolf-Karsten Hofmann, MD PhD, Detlef Haase

Blood (2014) 124 (21): 4656.

https://doi.org/10.1182/blood.V124.21.4656.4656

Published: 2014

Journal Articles

Therapy With Demethylating Agents Significantly Improves Overall- and AML-Free Survival In Patients With MDS Classified As High-Risk By IPSS Or Very High Risk By IPSS-R and Partial Or Total Monosomy 7-Results From a German Multicenter Study

Julie Schanz, MD, Friederike Braulke, Katayoon Shirneshan, PhD, Kathrin Nachtkamp, MD, Ulrich Germing, MD, Stephan Schmitz, MD, Peter Haas, MD, Michael Lübbert, MD, Catharina Müller-Thomas, MD, Katharina Götze, Uwe Platzbecker, MD, PhD, Florian Nolte, MD, Wolf-Karsten Hofmann, MD, Detlef Haase, MD

Blood (2013) 122 (21): 2784.

https://doi.org/10.1182/blood.V122.21.2784.2784

Published: 2013

Journal Articles

Influence of Different Genetic Alterations On the Engraftment Capacity and Serial Transplantation Efficiency of AML Patient-Derived Bone Marrow and Peripheral Blood Cells in NSG Mice

Julia Schüler, Peter Haas, MD, Kerstin Klingner, Björn W. Hackanson, MD, Heinz-Herbert Fiebig, Michael Lübbert, MD, PhD

Blood (2012) 120 (21): 3511.

https://doi.org/10.1182/blood.V120.21.3511.3511

Published: 2012

Journal Articles

Sensitive Detection of Renal Function in Multiple Myeloma (MM) Patients (pts) Via Estimated Glomerular Filtration Rate (eGFR) Unmasks Manifest Renal Function in Pts Receiving Lenalidomide and Suggests to Serve as An Additional Predictive Tool of Treatment Response.

Martina Kleber, MD, Peter Haas, Bernd Koch, Manuela Burbeck, Monika Engelhardt

Blood (2009) 114 (22): 4945.

https://doi.org/10.1182/blood.V114.22.4945.4945

Published: 2009

Journal Articles

Sequential Cytogenetic Analyses of 577 Patients with Myelodysplastic Syndromes: Correlations between Initial Karyotype, Cytogenetic Dynamics, and Clinical Course.

Christian Steidl, MD, Rainer Schabla, MD, Ulrich Germing, MD, PhD, Barbara Hildebrandt, PhD, Thomas Noesslinger, MD, Michael Pfeilstoecker, MD, PhD, Aristoteles Giagounidis, MD, PhD, Regina Kunzmann, PhD, Peter Haas, MD, Michael Luebbert, MD, PhD, Lorenz Truemper, MD, PhD, Detlef Haase, MD, PhD

Blood (2005) 106 (11): 2531.

https://doi.org/10.1182/blood.V106.11.2531.2531

Published: 2005

Journal Articles

Dose Reduction of Thalidomide in Multiple Myeloma: A Feasible Option without Reducing of Efficacy.

Peter Haas, MD, Ulrich Denz, MD, Gabriele Ihorst, Monika Engelhardt, MD

Blood (2005) 106 (11): 5129.

https://doi.org/10.1182/blood.V106.11.5129.5129

Published: 2005

Journal Articles

Efficacy of Diverse High-Dose Regimens Followed by Autologous Peripheral Blood Stem Cell Transplantation in Consecutive Multiple Myeloma Patients: A Single Center Analysis over a 12 Year Period.

Peter Haas, MD, Kris Bauchmüller, Alexander Kühnemund, Gabriele Ihorst, Monika Engelhardt, MD

Blood (2005) 106 (11): 5478.

https://doi.org/10.1182/blood.V106.11.5478.5478

Published: 2005

Journal Articles

Sequential Cytogenetic Analysis of 322 Patients with Myelodysplastic Syndromes. Delineation of Genetic Evolution and Clinical Implications.

Christian Steidl, MD, Rainer Schabla, Ulrich Germing, MD, PhD, Barbara Hildebrandt, MD, Thomas Noesslinger, MD, Michael Pfeilstocker, MD, PhD, Peter Haas, MD, Michael Lübbert, MD, PhD, Lorenz H. Truemper, MD, PhD, Detlef Haase, MD, PhD

Blood (2004) 104 (11): 2368.

https://doi.org/10.1182/blood.V104.11.2368.2368

Published: 2004

NARROW

Clinical Characteristics and Treatment Allocations in Patients with Myelodysplastic Syndromes and Monosomy 7: Results from an International Multicenter Study Suggest That Hypomethylating Agents Significantly Improve Overall- and AML-Free Survival in Patients Classified As Very High Risk By IPSS-R

Therapy With Demethylating Agents Significantly Improves Overall- and AML-Free Survival In Patients With MDS Classified As High-Risk By IPSS Or Very High Risk By IPSS-R and Partial Or Total Monosomy 7-Results From a German Multicenter Study

Influence of Different Genetic Alterations On the Engraftment Capacity and Serial Transplantation Efficiency of AML Patient-Derived Bone Marrow and Peripheral Blood Cells in NSG Mice

Sensitive Detection of Renal Function in Multiple Myeloma (MM) Patients (pts) Via Estimated Glomerular Filtration Rate (eGFR) Unmasks Manifest Renal Function in Pts Receiving Lenalidomide and Suggests to Serve as An Additional Predictive Tool of Treatment Response.

Sequential Cytogenetic Analyses of 577 Patients with Myelodysplastic Syndromes: Correlations between Initial Karyotype, Cytogenetic Dynamics, and Clinical Course.

Dose Reduction of Thalidomide in Multiple Myeloma: A Feasible Option without Reducing of Efficacy.

Efficacy of Diverse High-Dose Regimens Followed by Autologous Peripheral Blood Stem Cell Transplantation in Consecutive Multiple Myeloma Patients: A Single Center Analysis over a 12 Year Period.

Sequential Cytogenetic Analysis of 322 Patients with Myelodysplastic Syndromes. Delineation of Genetic Evolution and Clinical Implications.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only